How Thermo Fisher's Targeted Acquisitions and Divestitures are Shaping Its Future in 2026

Thermo Fisher Scientific’s Strategic Moves and Market Performance in 2026

Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has recently undertaken significant strategic initiatives aimed at refining its business focus and enhancing shareholder value. These developments have had a notable impact on the company’s stock performance.

Divestiture of Microbiology Business

In April 2026, Thermo Fisher announced a definitive agreement to sell its microbiology business to Astorg, a prominent private equity firm, for approximately $1.075 billion. This segment, which generated $645 million in revenue in 2025, specializes in antimicrobial susceptibility testing and culture media solutions. Marc N. Casper, the company’s chairman and CEO, stated that this transaction reflects active management of the company and provides additional capital to create shareholder value.

Acquisition of Clario Holdings

In October 2025, Thermo Fisher entered into an agreement to acquire Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, for $8.875 billion in cash. This acquisition is expected to be immediately accretive to adjusted earnings per share and aims to strengthen Thermo Fisher’s position as a trusted partner to pharmaceutical and biotechnology customers by delivering deeper clinical insights.

Financial Performance

Thermo Fisher’s financial results for the first quarter of 2026 demonstrated robust growth. The company reported a 6% increase in revenue, reaching $11.01 billion, and an 11% rise in GAAP diluted earnings per share to $4.43. Adjusted earnings per share grew by 6% to $5.44. These results underscore the effectiveness of the company’s growth strategy and operational excellence.

Stock Performance

As of July 17, 2026, Thermo Fisher’s stock (TMO) was trading at $532.48, reflecting a 1.23% decrease from the previous close. The stock’s performance is influenced by the company’s strategic decisions, financial results, and broader market conditions.

Conclusion

Thermo Fisher Scientific’s recent strategic initiatives, including the divestiture of its microbiology business and the acquisition of Clario Holdings, demonstrate a focused approach to enhancing its core competencies and delivering value to shareholders. These moves, coupled with strong financial performance, position the company for sustained growth in the life sciences and diagnostics sectors.